Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.
The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 +/- 9.5 and 2.40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia.
William E
WE
Delaney
Ros
R
Edwards
Danni
D
Colledge
Tim
T
Shaw
Phil
P
Furman
George
G
Painter
Stephen
S
Locarnini
D000577:Amides / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D001555:Benzene Derivatives / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D006515:Hepatitis B virus / Q000187:drug effects*; D019259:Lamivudine / Q000494:pharmacology*; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects*
C471028:AT 130; C117212:AT 61; D000577:Amides; D019380:Anti-HIV Agents; D001549:Benzamides; D001555:Benzene Derivatives; D019259:Lamivudine